Genexine (XKRX:095700) Short-Term Debt : ₩45,559 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Short-Term Debt?

Genexine's Short-Term Debt for the quarter that ended in Mar. 2024 was ₩45,559 Mil.

Genexine's quarterly Short-Term Debt declined from Sep. 2023 (₩58,587 Mil) to Dec. 2023 (₩44,575 Mil) but then increased from Dec. 2023 (₩44,575 Mil) to Mar. 2024 (₩45,559 Mil).

Genexine's annual Short-Term Debt increased from Dec. 2021 (₩11,200 Mil) to Dec. 2022 (₩65,246 Mil) but then declined from Dec. 2022 (₩65,246 Mil) to Dec. 2023 (₩44,575 Mil).

Genexine Short-Term Debt Historical Data

The historical data trend for Genexine's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Short-Term Debt Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

No Debt

11,020.88

11,200.19

65,246.19

44,575.04

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															56,673.20	58,119.83	58,587.08	44,575.04	45,558.56

Genexine Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Genexine Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Genexine's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines